Last reviewed · How we verify
atezolizumab or durvalumab
Atezolizumab and durvalumab are monoclonal antibodies that block the PD-L1 protein, preventing cancer cells from evading the immune system.
Atezolizumab and durvalumab are monoclonal antibodies that block the PD-L1 protein, preventing cancer cells from evading the immune system. Used for Locally advanced or metastatic urothelial carcinoma, Locally advanced or metastatic non-small cell lung cancer, Locally advanced or metastatic triple-negative breast cancer.
At a glance
| Generic name | atezolizumab or durvalumab |
|---|---|
| Sponsor | Anhui Shi, MD |
| Drug class | PD-1/PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By blocking PD-L1, these drugs allow the immune system to recognize and attack cancer cells more effectively. This is an example of immunotherapy, which works by enhancing the body's natural defenses against cancer. Atezolizumab and durvalumab have been shown to improve outcomes in various types of cancer, including non-small cell lung cancer and urothelial carcinoma.
Approved indications
- Locally advanced or metastatic urothelial carcinoma
- Locally advanced or metastatic non-small cell lung cancer
- Locally advanced or metastatic triple-negative breast cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Muscle or bone pain
- Rash
Key clinical trials
- Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer (PHASE1, PHASE2)
- Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy (PHASE1)
- Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy (PHASE3)
- Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies (PHASE1, PHASE2)
- Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) (PHASE2)
- First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (PHASE1)
- Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer (PHASE1, PHASE2)
- Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- atezolizumab or durvalumab CI brief — competitive landscape report
- atezolizumab or durvalumab updates RSS · CI watch RSS
- Anhui Shi, MD portfolio CI